No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTVA240719P50000
- 0.27
- +0.08+42.11%
15min DelayClose Jul 1 15:59 ET
0.27High0.27Low
0.27Open0.19Pre Close1 Volume685 Open Interest50.00Strike Price27.00Turnover28.26%IV6.29%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.27Extrinsic Value100Contract SizeAmericanOptions Type-0.1540Delta0.0714Gamma192.98Leverage Ratio-0.0209Theta-0.0037Rho-29.72Eff Leverage0.0279Vega
Intraday
- 5D
- Daily
News
Corteva Announces Dates for Second Quarter 2024 Earnings Release and Webcast
A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)
RBC Capital Maintains Corteva(CTVA.US) With Buy Rating, Cuts Target Price to $62
How Is Corteva's Stock Performance Compared to Other Agriculture Stocks?
Why Is Corteva, Inc. (CTVA) the Best Farmland and Agriculture Stock to Buy According to Hedge Funds?
Express News | Corteva Inc : RBC Cuts Target Price to $62 From $64
Comments
Morning Movers
Gapping up
$Citigroup(C.US$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock(BLK.US$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life(GL.US$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...
Gapping up
$Citigroup(C.US$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock(BLK.US$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life(GL.US$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...
27
1
Corteva's rising ROCE and efficient capital use are promising, but growing current liabilities may pose new risks. Despite this, the stock has given a decent 23% return over the past three years, indicating these developments are gaining deserved attention.
1
Corteva's high P/E ratio is sustained by its projected growth surpassing the broader market. Shareholders are at ease with the P/E, confident in the company's future earnings. The share price isn't anticipated to drop significantly soon under these conditions.
The CEO of Lavie Bio, Amit Noam, expressed satisfaction at achieving this milestone with Corteva, stating that the agreement showcases Lavie Bio's technological capabilities and enables the swift introduction of groundbreaking ag-biological solutions.
Corteva's guidance dispels concerns of lower earnings due to falling crop prices. Aptiv's 2024 forecast predicts a 7% sales growth despite stagnant global auto production. TD Cowen analyst Gautam Khanna deems Trane's results as 'good enough', rating the stock as Buy with a $235 price target.
Read more
Peanny : Based on Lies…. The truth is on its way.